Literature DB >> 26870359

TERT promoter mutations are rare in bone and soft tissue sarcomas of Japanese patients.

Tsuyoshi Saito1, Keisuke Akaike2, Aiko Kurisaki-Arakawa1, Midori Toda-Ishii2, Kenta Mukaihara2, Yoshiyuki Suehara3, Tatsuya Takagi3, Kazuo Kaneko3, Takashi Yao1.   

Abstract

Recurrent hot-spot mutations in the telomerase reverse transcriptase (TERT) promoter have been reported in various types of tumor. In several tumor types, TERT promoter mutations are associated with poor clinical outcomes. TERT promoter mutations are reported to be rare in soft tissue tumors, with the exception of myxoid liposarcoma (MLS). Our previous study reported that TERT promoter mutations occurred in a subset of solitary fibrous tumors (SFTs) and were associated with adverse clinical outcomes in Japanese individuals. The site-specific frequency (e.g. central nervous or soft tissue origin) of TERT promoter mutations in our SFT cases appeared to be different from previously reported values in a European population. These findings prompted the present study to elucidate the potential role of ethnic background in the different frequencies of TERT promoter mutations in bone and soft tissue sarcomas. In the present study, TERT promoter mutations were examined in 180 cases of bone and soft tissue sarcomas. TERT promoter region mutations were identified in 10 cases [5 SFTs, 3 MLSs, 1 undifferentiated pleomorphic sarcoma (UPS) and 1 malignant granular cell tumor]. All mutations were C228T. The frequencies of TERT promoter mutation in MLS and UPS were 23.1 (3/13) and 5% (1/20), respectively. Only 1/5 patients with TERT-mutated tumors experienced local recurrence or distant metastasis. The present study revealed the first case of a malignant granular cell tumor with a TERT promoter mutation and revealed that the frequency of TERT promoter mutations in MLSs of Japanese patients is lower compared with that reported in German patients, providing evidence of a possible ethnic difference in the frequency of TERT promoter mutations.

Entities:  

Keywords:  TERT; bone and soft tissue sarcoma; mutation

Year:  2015        PMID: 26870359      PMCID: PMC4726990          DOI: 10.3892/mco.2015.674

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  15 in total

Review 1.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

2.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Authors:  Iñigo Landa; Ian Ganly; Timothy A Chan; Norisato Mitsutake; Michiko Matsuse; Tihana Ibrahimpasic; Ronald A Ghossein; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-07-05       Impact factor: 5.958

Review 3.  The role of telomere biology in cancer.

Authors:  Lifeng Xu; Shang Li; Bradley A Stohr
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

4.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.

Authors:  Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-10-24       Impact factor: 17.088

5.  Malignant granular cell tumor of the ulnar nerve with novel cytogenetic and molecular genetic findings.

Authors:  Dionysios J Papachristou; Alka Palekar; Urvashi Surti; Kathleen Cieply; Richard L McGough; Uma N M Rao
Journal:  Cancer Genet Cytogenet       Date:  2009-05

6.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

7.  TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.

Authors:  Hendrikus J Dubbink; Hannah Bakels; Edward Post; Ellen C Zwarthoff; Robert M Verdijk
Journal:  J Neurooncol       Date:  2014-07-18       Impact factor: 4.130

8.  Malignant granular cell tumor of the lateral femoral cutaneous nerve: report of a case with cytogenetic analysis.

Authors:  Luca Di Tommaso; Elisabetta Magrini; Alessandro Consales; Massimo Poppi; Gianandrea Pasquinelli; Tsering Dorji; Giovanni Benedetti; Paola Baccarini
Journal:  Hum Pathol       Date:  2002-12       Impact factor: 3.466

9.  TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.

Authors:  Klaus G Griewank; Bastian Schilling; Rajmohan Murali; Nicola Bielefeld; Marion Schwamborn; Antje Sucker; Lisa Zimmer; Uwe Hillen; Jörg Schaller; Thomas Brenn; Dirk Schadendorf; Thomas Mentzel
Journal:  Mod Pathol       Date:  2013-09-13       Impact factor: 7.842

10.  TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.

Authors:  Christian Koelsche; Marcus Renner; Wolfgang Hartmann; Regine Brandt; Burkhard Lehner; Nina Waldburger; Ingo Alldinger; Thomas Schmitt; Gerlinde Egerer; Roland Penzel; Eva Wardelmann; Peter Schirmacher; Andreas von Deimling; Gunhild Mechtersheimer
Journal:  J Exp Clin Cancer Res       Date:  2014-04-11
View more
  8 in total

1.  Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.

Authors:  Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah
Journal:  Lab Invest       Date:  2016-06-06       Impact factor: 5.662

2.  Detection of Aberrant TERT Promoter Methylation by Combined Bisulfite Restriction Enzyme Analysis for Cancer Diagnosis.

Authors:  Seungjae Lee; Sumit Borah; Armita Bahrami
Journal:  J Mol Diagn       Date:  2017-03-09       Impact factor: 5.568

3.  TERT promoter mutations and prognosis in solitary fibrous tumor.

Authors:  Armita Bahrami; Seungjae Lee; Inga-Marie Schaefer; Jennifer M Boland; Kurt T Patton; Stanley Pounds; Christopher D Fletcher
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

Review 4.  Telomere maintenance in soft tissue sarcomas.

Authors:  Nicholas Eastley; Barbara Ottolini; Carmen Garrido; Jacqueline A Shaw; Thomas Alasdair McCulloch; Robert U Ashford; Nicola J Royle
Journal:  J Clin Pathol       Date:  2017-02-09       Impact factor: 3.411

5.  Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.

Authors:  Monica S Ventura Ferreira; Martina Crysandt; Till Braunschweig; Edgar Jost; Barbara Voss; Anne-Sophie Bouillon; Ruth Knuechel; Tim H Brümmendorf; Fabian Beier
Journal:  Int J Mol Sci       Date:  2018-02-18       Impact factor: 5.923

6.  High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis.

Authors:  Junko Kunieda; Kyoko Yamashita; Yuki Togashi; Satoko Baba; Seiji Sakata; Kentaro Inamura; Keisuke Ae; Seiichi Matsumoto; Rikuo Machinami; Masanobu Kitagawa; Kengo Takeuchi
Journal:  Cancer Sci       Date:  2022-01-11       Impact factor: 6.716

Review 7.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene.

Authors:  Muhammad Khairul Ramlee; Jing Wang; Wei Xun Toh; Shang Li
Journal:  Genes (Basel)       Date:  2016-08-18       Impact factor: 4.096

Review 8.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.